1.Omeñaca F, Muro M. Protocolos diagnósticos y terapéuticos en Pediatría. 2005. 4:27 – 36 2.Martínez JL. Anemia del prematuro. Estrategias terapéuticas. Abril 1999; 10 (1). 3.Domínguez F, y cols. Guías de Prácticas Clínicas en Neonatología. La Habana: Edit Ciencias Médicas 1999; 22: 199- 204 4.Ringer SA, Richardson DK, Sacher RA, Keszler M, Hallowell W. Variations in transfusion practice in neonatal intensive care unit. Pediatrics 1998; 101:194-200. 5.Obladen M, Sachsenweger M, Stahnke M. Blood sampling in very low birth weight infants receiving different levels of intensive care. Eur J Pediatr 1988; 147:399-404. 6.Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: A randomized, double-blind, placebo-controlled study. J Pediatr 1997; 131:661-665. 7.Shannon KM, Mentzer WC, Abels RI, Freeman P, Newton N, et al. Recombinant human erythropoietin in the anemia of prematurity: Results of a placebo-controlled pilot study. J Pediatr 1991; 118:949-955. 8.Lachance C, Cheessex P, Fouron JC, Widness JA, Bard H. Myocardial, erythropoietic, and metabolic adaptations to anemia of prematurity. J Pediatr 1994; 125:278-282. 9.X. Carbonell Estrany, J. Figueras Aloy, J.Mª Pérez Fernández, A. Fernández López, G. González Luis, M.D. Salvía Roiges. Utilidad de la eritropoyetina en el tratamiento de la anemia de la prematuridad. Influencia del peso de nacimiento. Anales españoles de Pediatría. 1999. Vol 51 Nº 3: 281-282. 10.Escalante ER. Anemias del recién nacido. Guía para el uso de eritropoyetina. Rev Hosp Mat Inf Ramón Sardá. 2001; 20 (3). 11.Salvado GA, Ramolfo P, Escobar M, Núñez A, Aguayo I, Standen J, et al. Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro. Rev Med Chile 2000; 128:1313-17. 12.Goodman & Gilman´s. The Pharmacology Diseases and Therapeutics. USA: Medical Publishing Division. Mc Graw-Hill.2001:1487-1494. 13.Escalante ER, Luchtenberg G, Sola H. Eritropoyetina recombinante. Actualización. Rev Hosp Mat Inf Ramón Sardá. 1996; XV(2). 14.Obladen M, Maier R, Segerer H, Grauel EL, Holland BM, Stewart G, et al. Efficacy and safety of recombinant human erythropoietin to prevent the anemias of prematurity. European Randomized Multicentre Trial. Contributions to Nephrology 1991; 88:314-26. 15.Kacho MA, Zahedpasha Y, Hajian K, Moradi S. The effect of human recombinant erythropoietin on prevention of Anemia of Prematurity. Iran J Ped 2007;17(3):257-262. 16.Chávez LA, Flores NG. Uso de Eritropoyetina Recombinante Humana (r-HuEPO) para evitar anemia en pacientes pretérminos . Rev Hosp M Gea Glez 2000; 3(4):157-162. 17.Barrio A, Guemes M. Evolución del consumo de eritropoyetina en un hospital general durante el período 1991-1999.http://abgf@bio.hgy.es. 18.Donato H; Ferro H. Tratamiento con eritropoyetina humana recombinante. Medicina (B Aires) 2006; 66(1):51-69. 19.Strauss RG. Controversies in the management of the anaemia of prematurity using single-donor red blood cell transfusions and/or recombinant human erythropoietin. Transfus Med Rev 2006 Jan; 20 (1):34-44. 20.Manoura A; Korakaki E; Hatzidaki E: Saitakis E; Maraka S. Use of recombinant erythropoietin for the management of severe Hemolytic Disease of the Newborn of a KO phenotype mother. Pediatr Hematol Oncol 2007 Jan-Feb; 24(1):69-73. 21.Stockman JA 3rd, Oski FA. Physiological anaemia of infancy and the anaemia of prematurity. Clinics in Hematology 1978;7:3-18. 22.Strauss RG. Current issues in neonatal transfusions. Vox Sanguinis 1986;51:1-9. 23.Stockman JA 3rd. Anemia of prematurity. Current concept in the issue of when to transfuse. Pediatric Clinics of North America 1986;33:111-28. 24.Ohls RK. Erythropoietin treatment in extremely low birth weight infants: blood in versus blood out. Journal of Pediatrics 2002;141:3-6. 25.Widness JA, Seward VJ, Kromer IJ, Burmeiser LF, Bell EF, Strauss RG. Changing patterns of red blood cell transfusion in very low birth weight infants. Journal of Pediatrics 1996;129:680-7. 26.Aher S, Ohlsson A. Eritropoyetina tardía para la prevención de la transfusión de eritrocitos en neonatos prematuros y/o de bajo peso al nacer. Revisión Cochrane. Biblioteca Cochrane Plus, 2008, Número 2. 27.Ohls RK. The use of erythropoietin in neonates. Clinics in Perinatology 2000;27:681-96. 28.Kotto-Kome AC, Garcia MG, Calhoun DA, Christensen RD. Effect of beginning recombinant erythropoietin treatment within the first week of life among very-low-birth-weight neonates, on "early" and "late" erythrocyte transfusions: a meta-analysis. Journal of Perinatology 2004;24:24-9. 29.García MG, Hutson AD, Chrisensen RD. Effect of recombinant erythropoietin on "late" transfusions in the neonatal intensive care unit: a meta-analysis. Journal of Perinatology 2002;22:108-11. 30.Zipursky A. Erythropoietin therapy for premature infants: Cost without benefit?. Pediatric Research 2000;48:136. 31.Hesse L, Eberl W, Schlaud M, Poets CF. Blood transfusion. Iron load and retinopathy of prematurity. European Journal of Pediatrics 1997;156:465-70. 32.Informe Final del Ensayo Clínico Fase III. Efectividad y seguridad del uso del ior®EPOCIM en la profilaxis y tratamiento de la anemia en el recién nacido prematuro. Habana. CIMAB. 2011 33.Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004865. 34.Figueras-Aloy J, Alvarez-Domínguez E, Morales-Ballus M, Salvia-Roiges MD, Moretones-Suñol G. Early administration of erythropoietin in the extreme premature, a risk factor for retinopathy of prematurity?. An Pediatr (Barc). 2010 Dec;73(6):327-33. 35.Shah N, Jadav P, Jean-Baptiste D, Weedon J, Cohen LM, Kim MR. The effect of recombinant human erythropoietin on the development of retinopathy of prematurity. Am J Perinatol. 2010 Jan;27(1):67-71. 36.Sola A, Brown MS, Phibbs RH. Cuidados especiales del feto y el recién nacido. 2000; 5: 630-665. 37.Aguilar MJ, Jiménez FG, Martínez MZ, Cabañas JG, Muñoz DH, González DR, Caballero PJ. Profilaxis de la anemia de la prematuridad con eritropoyetina. Estudio caso-control. An Esp Ped.2000;53 (3):243-8. 38.Nathan DG, Oski SH. Hematology of infancy and childhood. 5 ed. Philadelphia: WB Saunders, 1998; 1149-82. 39.Haiden N, Cardona F, Schwindt J, Berger A, Kulhe S, Homoncik M, et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity. Thombosis and Haemostasis 2005; 93:118-23. 40.Maier RF, Obladen M, Kattner E, Natzschka J, Messer J, Regazzoni BM, et al. High versus low-dose erythropoietin in extremely low birth weight infants. Journal of Pediatrics 1998; 132:866-70. 41. Carnielli VP, Riol RD, Montini G. Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Archives of Disease in Childhood Fetal Neonatal Edition 1998; 79:F44-8. 42. Lauterbach R, Kachlik P, Pawlik D, Bajorek I. Evaluation of treatmment results for anemia of prematurity treated with various doses of human recombinant erythropoietin. Pediatrid Polska 1995; 70:739-44. 43. Meyer MP, Sharma E, Carsons M. Recombinant erythropoietin and blood transfusion in selected infants. Archives of Disease in Childhood Fetal Neonatal Edition 2003; 88:F41-5. 44. Maier RF, Obladen M, Muller-Hansen I, Kattner E, Merz U, Arlettaz R, et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. Journal of Pediatrics 2002;141:8-15. 45.Carbonell-Estrany X, Figueras-Aloy J, Alvarez E. Erythropoietin and prematurity- where do we stand? J Perinat Med 2005; 33(4):277-86. 46. Avent M, Cory BJ, Galpin J, Ballot DE, Cooper PA, Davies VA. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. Journal of Tropical Pediatrics 2002; 48:227-33. 47.Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korenes SB, Stoll BJ, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter , randomized, controlled trial. Pediatrics 2001; 108:934-42. 48. Arif B, Ferhan K. Recombinant human erythropoietin therapy in low- birthweight preterm infants: a prospective controlled study. Pediatrics International 2005; 47:67-71. 49.Sola A. Diálogos en Neonatología: aprendiendo de las preguntas. 1ª ed. Buenos Aires: Edimed-Ediciones Médicas, 2009: 166. 50.Halperin DS, Wacker P, Lacourt G, Felix M, Babel JF, Aapro M, et al. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: a pilot study. J Pediatr 1990; 116: 779-786. 51. Shannon K, Mentzer W, Abels RJ, Freeman P, Newton N, Thompson D, et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo- controlled pilot study. J Pediatr 1991; 118:949-955. 52.Meister B, Maurer H, Simma B, Kern H, Ulmer H, Hittmair A, Fink FM. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants. Stem cells 1997; 15(5):359-63. 53.Stoll BJ, Kliegman R. Trastornos hematológicos. En: Nelson. Tratado de Pediatría 2004; XX:1 (92):599-607. 54.Finch CA. Erythropoiesis, erythropoietin and iron. Blood 1982; 60:1241-6. 55.Genen LH, Klenoff H. Iron supplementation for erythropoietin – treated preterm infants (Protocol). The Cochrane Database of Systematic Reviews 2001; (1). 56. Kling PJ, Winzerling JJ. Iron status and the treatment of the anemia of prematurity. Clinics in Perinatology 2002; 29:283-94. 57. Shannon KM, Keith JF 3rd, Mentzer WC, Ehrenkranz RA, Brown MS, Widness JA, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 1995; 95:1-8. 58. Friel JK; Aziz K; Andrews WL; Serfass RE. Iron absorption and oxidant stress during erythropoietin therapy in very low birth weight premature infants: a cohort study. BMC Pediatr 2005; 5:29. 59. Romagnoli C, Zecca E, Gallini F, Girlando P, Zuppa AA. Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity? European Journal of Pediatrics 2000;159:627-8. 60.Musante G, Gederlini A, Prudent L. Treatment with erythropoietin and incidence of prematurity in ELBW infants. In: Pediatric Academy Societes’2006 Annual Meeting.http:www.abstracts2view.com/pas/.2006 61.Morita M, Ohneda O, Yamashita T, Takahashi s, Suzuki ST, Nakajima O, et al. HLF/HIF-2 alpha is a key factor in retinopathy of prematurity in association with erythropoietin. The EMBO Journal 2003; 22:1134-46. 62.Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. NEJM (New England Journal of Medicine) 2005; 353:782-92. 63.Manzoni P, Maestri A,Gomirato G, Takagi H, Watanabe D, Matsui S. Erythropoietin as a retinal angiogenic factor. NEJM 2005; 353:2190-1. 64.Shah NC, Kim R, Jadav P, Cohen LM, Jean Baptiste D, Weedon J. Effect of recombinant human erythropoietin on the development of retinopathy of prematurity. Pediatric Research 2005; 57:546A (abstract). 65.Ohlsson A, Aher SM. Eritropoyetina temprana para la prevención de la transfusión de eritrocitos en neonatos prematuros y/o de bajo peso al nacer (Cochrane Review). In: La Biblioteca Cochrane Plus, 2007,Issue 4 Oxford: Update Software. 66.Liu A, Fayard E,Dunbar J, Chan A, Niemeyer M. High-dose recombinant human erythropoietin may increase the incidence and severity of ROP in premature infants. In: http://www.abstracts2view.com/pas/.2006. 67.Amiel-Tison C. Update of the Amiel-Tison neurologic assessment for the term neonate or at 40 weeks corrected age. Pediatr Neurol 2002:7: 196-202. 68.Bayley N. Manual for the Bayley scales of infant developmennt. New York: Psichological Corporation, 1969.
Versión para impresión